ACLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arcellx Inc (ACLX) is not a strong buy for a beginner investor with a long-term horizon at this time. The stock's recent price decline, lack of proprietary trading signals, weak financial performance, and mixed analyst sentiment suggest that it may be prudent to hold off on investing until clearer positive catalysts emerge.
The stock is showing bearish momentum with a regular market price decline of -3.64%. The MACD is negatively expanding, and RSI is neutral at 36.328, suggesting no clear reversal signal. The stock is trading near its support level (S1: 66.624), which could provide temporary stability, but overall, the technical indicators do not suggest a strong buy opportunity.
Analysts from UBS and Wells Fargo maintain a bullish long-term outlook on the company's lead asset, anito-cel, with price targets of $
The company's innovative CAR-T therapy has potential for rapid market uptake upon launch in 2026.
Rothschild & Co downgraded the stock to Neutral, citing increased competition in the CAR-T space and reduced sales estimates.
First Turn Management sold its entire stake, signaling reduced confidence in the company's growth prospects.
Financial performance in Q3 2025 shows a significant revenue decline (-80.99% YoY) and continued net losses.
The stock underperformed the S&P 500 by 4.3% over the past year.
In Q3 2025, Arcellx reported a significant revenue drop of -80.99% YoY to $4.95 million. However, net income improved to -$55.78 million (+115.65% YoY), and EPS increased to -0.99 (+106.25% YoY). While gross margin remains at 100%, the overall financials indicate weak growth and profitability.
Analyst sentiment is mixed. UBS and Wells Fargo maintain Buy ratings with a $100 price target, citing long-term potential for anito-cel. However, Rothschild & Co downgraded the stock to Neutral with a reduced price target of $82, reflecting concerns over competition and lower sales estimates.
